Related references
Note: Only part of the references are listed.Immune Checkpoint Inhibitors in Transplantation-A Case Series and Comprehensive Review of Current Knowledge
Julie Delyon et al.
TRANSPLANTATION (2021)
PD-1 inhibitor as bridge therapy to liver transplantation?
Parissa Tabrizian et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2021)
Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?
Mina F. Nordness et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2020)
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial
Birgit Geoerger et al.
LANCET ONCOLOGY (2020)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma
Reid W. Merryman et al.
BLOOD (2017)
Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma
Teresa C. Longoria et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
A review of 218 pediatric cases of hepatocellular carcinoma
Bassan J. Allan et al.
JOURNAL OF PEDIATRIC SURGERY (2014)
Share Paper
